Sci-Tech Innovation Board Medical ETF Huaxia rises nearly 1%, institutions say pharma valuations and defensive attributes stand out

Jiemian··Read original
2▲3 ▼0Impact / 5
Summary · why it matters

The Sci-Tech Innovation Board Medical ETF Huaxia rose 0.66%, heading for a fifth straight gain, with the latest price at 1.07 yuan. As of 1:49 PM on July 3, 2026, the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index surged 1.11%, with constituent Olin Bio up 8.77%, Dizal Pharmaceutical up 7.79%, and MGI Tech up 6.57%. In related news, the 12th round of national centralized drug procurement explicitly includes only mature generics, while innovative drugs still under patent protection are excluded, signaling a policy shift from cost control and price cuts to supporting and strengthening the industry. Zhongtai Securities noted that the pharmaceutical sector's valuation attractiveness and defensive attributes are prominent, with signs of bottoming and recovery emerging at the end of June, especially in CXO and innovative drugs, and recommended focusing on the internationalization of innovative drugs and CRO/CDMO performance delivery targets. The Sci-Tech Innovation Board Medical ETF Huaxia closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index, which selects 50 listed companies in biomedical and related fields on the Sci-Tech Innovation Board as samples, with the top ten holdings accounting for 51.84% of the total.

Impact on assets 4

Others▲ · 4 stocks
MGI Tech Co. Ltd. A
688114
▲ PositiveRegulationrelevance

Policy shift from cost control to supporting innovation benefits MGI Tech as a biomedical company.

© 2026 MarketIVNews